Forte Biosciences (FBRX) Tax Provisions (2018 - 2026)

Forte Biosciences' (FBRX) quarterly Tax Provisions came in at $373000.0 in Q1 2026, up 121.95% on a QoQ basis from -$1.7 million in Q4 2018.

Forte Biosciences (FBRX) Tax Provisions (2018 - 2026) Analysis & Trends

Forte Biosciences (FBRX) has 2 years of Tax Provisions data on file, last reported at $373000.0 in Q1 2026.

On a quarterly basis, Tax Provisions changed N/A year-over-year to $373000.0 in Q1 2026; TTM through Mar 2026 was -$1.3 million, a 597.89% decrease from a year earlier, with the FY2025 full-year figure at $1.0 million, up 113.92% from the prior year.
Tax Provisions for Q1 2026 stood at $373000.0, up from -$1.7 million in the prior quarter.
Over the last five years, Tax Provisions for FBRX reached as high as $373000.0 in Q1 2026 and fell as low as $373000.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Taxes (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	125,146.46
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-859,000.00
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	31.86 Mn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	221.50 Mn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	104.00 Mn
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	-60.00 Mn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	-
10	Forte Biosciences	994.79 Mn	936.59 Mn	-	373,000.00

Download Data